ArunA Biomedical Commences New Class of Exosome Biologics to Cure Central Nervous System and Neurodegenerative Disorders

ArunA Biomedical officially launches of a new class exosome biologics to cure central nervous system and neurogenerative disorders. The company published conclusions of a study conducted in Translational stroke research that inferred extracellular vesticles yielded from human neural stem cells improved tissue witnessing recovery in murine thromboembolic stroke models.

Dr. Steven Stice, a Georgia Research Alliance Scholar sphearheaded the study who also serves as co- founder, CEO for ArunA Biomedical. Neural stem cell (NSC) and mesenchymal stem cells (MSC) were assessed for changes in infarct volume as well as sensorimotor function. Outcomes showed that NSC Evs accelerated tissue and functional consequences in middle aged rodents whereas MSC EVs were less responsive. MRI in aged rodents were testament to stark distinctions in lesion volumes that used NSC EV treatment. NSC EV surged T Cell numbers known to aggravate remyelination in the affected brain. Neural stem cell EV treatments hints significant implications on motor function as indicated by beam walk, instances of foot faults and strength evaluated by a hanging wire test. Increased time with a novel object supports improved episodic memory formation in the rodent.

Investigators have been able to apply the same results on unique large animal model of stroke as developed at the University Of Georgia, results of which will be published in a journal after extensive appraisal in the next few months.

Dr. Stice commented ‘’ Buoyed by the results of this study and our additional pre-clinical models and internal in vitro studies, we will rapidly move toward the clinic with a plan to initiate first-in-human studies in 2019.”.

Dr. Stice exhibits profound professionalism in developing the first human pluripotent stem cell for research enabling its usage throughout the biotechnology and pharmaceutical industries. This has remarkably led to initiation of intact , stable neural cell line that assures world-class technology in the production of exosomes.

Later, ArunA Biomedical plans to foray into drug delivery platform as well as pre-clinical studies in epilepsy, traumatic brain and spinal cord injuries in 2018.